A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
← catalyst calendarNCT06015737 · readout in 75 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
339actual
Sites
188
Countries
Argentina, Australia, Austria +29
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-29 | actual | When the study began enrolling |
| Primary completion | 2026-11-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-08-10 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cutaneous Lupus Erythematosus
Interventions
- Combination product: Anifrolumab
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score
measured At Week 24
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed